
---
title: '新冠抗原自测产品上市，市场规模或超2000亿元。本周A股解禁市值200亿元，7连板牛股在列（附股）'
categories: 
 - 金融
 - 证券时报网
 - 数据
headimg: 'https://data.stcn.com/djsj/202203/W020220314295124111333.png'
author: 证券时报网
comments: false
date: Mon, 14 Mar 2022 07:59:00 GMT
thumbnail: 'https://data.stcn.com/djsj/202203/W020220314295124111333.png'
---

<div>   
<p mp-original-font-size="16" mp-original-line-height="25.600000381469727"><strong><span mp-original-font-size="16" mp-original-line-height="25.600000381469727">五款新冠抗原自测产品正式上市</span></strong></p><p mp-original-font-size="16" mp-original-line-height="28.799999237060547">3月11日，国家卫健委印发《新冠病毒抗原检测应用方案（试行）》。《方案》规定抗原检测的适用人群：一是到基层医疗卫生机构就诊，伴有呼吸道、发热等症状且出现症状5天以内的人员；二是隔离观察人员；三是有抗原自我检测需求的社区居民。居民可通过零售药店、网络销售平台等渠道，自行购买抗原检测试剂进行自测。</p><p mp-original-font-size="16" mp-original-line-height="28.799999237060547"><span mp-original-font-size="16" mp-original-line-height="28.799999237060547">同日，国家药监局批准北京华科泰生物的新冠抗原产品自测应用申请变更；次日，国家药监局再度批准南京<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS688105" code="688105">诺唯赞</a>、北京金沃夫、深圳华大因源、广州<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300482" code="300482">万孚生物</a>的新冠抗原产品自测应用申请变更。</span>至此，五款新冠抗原自测产品正式上市。截至目前，多家连锁药房及医药电商平台公告称，已与<span mp-original-font-size="16" mp-original-line-height="28.799999237060547"><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300482" code="300482">万孚生物</a></span>等获批厂家达成合作，自测产品将于近日上架销售。</p><p style="text-align:center"><img src="https://data.stcn.com/djsj/202203/W020220314295124111333.png" title="7521647181855_.pic_hd.jpg" alt="7521647181855_.pic_hd.jpg" width="300px" height="649.2753623188405px" style="width: 300px; height: 649.275px;" oldsrc="W020220314295124111333.png" referrerpolicy="no-referrer"></p><p mp-original-font-size="16" mp-original-line-height="28.799999237060547"><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600369" code="600369">西南证券</a>表示，新冠抗原产品具备使用方便、减少人群聚集、成本低廉和时间迅速等众多优势。<span mp-original-font-size="16" mp-original-line-height="28.799999237060547">目前我国疫情呈现多地散发的严峻态势，国家决定在核酸检测的基础上，增加抗原检测作为补充，未来市场空间可期。</span><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600918" code="600918">中泰证券</a>参考海外新冠抗原自检试剂盒发放政策，预计国内新冠抗原自检试剂盒市场单月规模有望达177-266亿元，年市场规模将达2124-3192亿元。</p><p mp-original-font-size="16" mp-original-line-height="28.799999237060547">证券时报·数据宝梳理部分新冠抗原产品产业链个股名单。2月至今，17股涨逾10%，<span mp-original-font-size="16" mp-original-line-height="28.799999237060547"><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS688075" code="688075">安旭生物</a></span>涨幅高达82.08%，其后<span mp-original-font-size="16" mp-original-line-height="28.799999237060547"><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS688575" code="688575">亚辉龙</a></span>、<span mp-original-font-size="16" mp-original-line-height="28.799999237060547"><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300482" code="300482">万孚生物</a></span>涨幅突破60%。大部分检测业务个股业绩高增，<span mp-original-font-size="16" mp-original-line-height="28.799999237060547"><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS688068" code="688068">热景生物</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002432" code="002432">九安医疗</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300406" code="300406">九强生物</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002932" code="002932">明德生物</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS688298" code="688298">东方生物</a></span>等5股全年净利润翻倍，抗原产品刚获批准的<span mp-original-font-size="16" mp-original-line-height="28.799999237060547"><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300482" code="300482">万孚生物</a></span>尚未发布相关报告。机构对于<span mp-original-font-size="16" mp-original-line-height="28.799999237060547"><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS603259" code="603259">药明康德</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002821" code="002821">凯莱英</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300363" code="300363">博腾股份</a></span>等口服药业务个股关注度较高，评级机构均在20家上下。</p><p style="text-align:center"><img src="https://data.stcn.com/djsj/202203/W020220314295124204836.png" title="6951647170689_.pic.jpg" alt="6951647170689_.pic.jpg" width="300px" height="328.24760244115083px" style="width: 300px; height: 328.248px;" oldsrc="W020220314295124204836.png" referrerpolicy="no-referrer"></p><p mp-original-font-size="16" mp-original-line-height="25.600000381469727"><strong><span mp-original-font-size="16" mp-original-line-height="25.600000381469727">本周35股面临解禁，</span>解禁市值206.51亿元</strong></p><p mp-original-font-size="16" mp-original-line-height="28.799999237060547">数据宝统计，剔除即将上市新股，本周A股市场将有35股面临解禁。按照最新收盘价计算，35股合计解禁市值206.51亿元，为截至目前2022年解禁市值最低的一周。</p><p mp-original-font-size="16" mp-original-line-height="28.799999237060547">市值规模方面，7股解禁市值逾10亿元。<span mp-original-font-size="16" mp-original-line-height="28.799999237060547"><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002951" code="002951">金时科技</a></span>以40.03亿元居首，<span mp-original-font-size="16" mp-original-line-height="28.799999237060547"><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300762" code="300762">上海瀚讯</a></span>35.92亿元，以上两股解禁股均为首发原股东限售股份。其后<span mp-original-font-size="16" mp-original-line-height="28.799999237060547"><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300953" code="300953">震裕科技</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600267" code="600267">海正药业</a></span>解禁市值在20亿元以上，前者为首发原股东限售和首发战略配售股份，后者则为定向增发机构配售股份。</p><p mp-original-font-size="16" mp-original-line-height="28.799999237060547">13股解禁市值不足亿元，<span mp-original-font-size="16" mp-original-line-height="28.799999237060547"><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300782" code="300782">卓胜微</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300639" code="300639">凯普生物</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS603279" code="603279">景津装备</a></span>解禁市值低于一千万元；最小的一笔解禁来自于<span mp-original-font-size="16" mp-original-line-height="28.799999237060547"><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS603977" code="603977">国泰集团</a></span>，为其他类型的解禁股，金额仅626.5元。</p><p mp-original-font-size="16" mp-original-line-height="28.799999237060547"><span mp-original-font-size="16" mp-original-line-height="28.799999237060547">相较于解禁市值，解禁比例对于股价的冲击更为直观。</span>数据宝统计，35股中，<span mp-original-font-size="16" mp-original-line-height="28.799999237060547"><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002951" code="002951">金时科技</a></span>解禁比例居首，高达82.3%，解禁股来自于公司第一、第二大股东。该股最新价12.01元/股，后复权股价相对发行价累计上涨27.23%。其后<span mp-original-font-size="16" mp-original-line-height="28.799999237060547"><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS688316" code="688316">青云科技</a>-U、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300762" code="300762">上海瀚讯</a></span>解禁比例逾40%；<span mp-original-font-size="16" mp-original-line-height="28.799999237060547"><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS688456" code="688456">有研粉材</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300953" code="300953">震裕科技</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600774" code="600774">汉商集团</a></span>超20%。与当前相比，<span mp-original-font-size="16" mp-original-line-height="28.799999237060547"><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002951" code="002951">金时科技</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS688316" code="688316">青云科技</a>-U、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS688456" code="688456">有研粉材</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300953" code="300953">震裕科技</a></span>等4股解禁后，各自A股流通盘将增加100%以上。</p><p style="text-align:center"><img src="https://data.stcn.com/djsj/202203/W020220314295124276505.png" title="6881647165654_.pic.jpg" alt="6881647165654_.pic.jpg" width="300px" height="421.66666666666663px" style="width: 300px; height: 421.667px;" oldsrc="W020220314295124276505.png" referrerpolicy="no-referrer"></p><p mp-original-font-size="16" mp-original-line-height="25.600000381469727"><strong><span mp-original-font-size="16" mp-original-line-height="25.600000381469727">14股年度业绩高增长</span></strong></p><p mp-original-font-size="16" mp-original-line-height="28.799999237060547">2月至今，上证指数走势趋弱，累计下跌1.54%。35股平均跌幅0.14%，<span mp-original-font-size="16" mp-original-line-height="28.799999237060547"><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002207" code="002207">准油股份</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ301060" code="301060">兰卫医学</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300639" code="300639">凯普生物</a></span>和<span mp-original-font-size="16" mp-original-line-height="28.799999237060547"><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS688707" code="688707">振华新材</a>-U</span>等4股涨逾25%。<span mp-original-font-size="16" mp-original-line-height="28.799999237060547">其中，近期七连板的<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002207" code="002207">准油股份</a>累计上涨65.87%，独占鳌头。</span>公司多次提示交易异常波动，公司业务收入绝大部分来源于国内油田技术服务，并无油气生产业务，国际油价上涨对业绩影响存在不确定性。8股股价跌逾10%，<span mp-original-font-size="16" mp-original-line-height="28.799999237060547"><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300953" code="300953">震裕科技</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS688667" code="688667">菱电电控</a></span>领跌，跌幅双双超过27%。</p><p mp-original-font-size="16" mp-original-line-height="28.799999237060547">数据宝统计，26股已发布年报/业绩预告。以年报数据/预告增长上限计算，14股净利润增幅超过60%，8股有望翻倍。<span mp-original-font-size="16" mp-original-line-height="28.799999237060547"><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600500" code="600500">中化国际</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS688707" code="688707">振华新材</a>-U、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ000821" code="000821">京山轻机</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002207" code="002207">准油股份</a></span>增幅最高，突破200%，依次为790%、353.62%、264.49%、220.49%。</p><p mp-original-font-size="16" mp-original-line-height="28.799999237060547"><span mp-original-font-size="16" mp-original-line-height="28.799999237060547"><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600500" code="600500">中化国际</a></span>预计2021年净利润同比增加584%-790%，主因行业景气周期以及处置子公司产生投资收益。<span mp-original-font-size="16" mp-original-line-height="28.799999237060547"><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS688707" code="688707">振华新材</a>-U</span>实现扭亏为盈，2021年动力电池市场快速增长，下游需求旺盛，公司正极材料销量及收入大幅增长。今年1-2月，公司正极材料销售继续强势，实现营收约16.26亿元，同比增长约180%。<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ000750" code="000750">国海证券</a>表示，公司产品结构优化，高镍三元上量提振盈利能力。作为单晶领先企业，产能扩张有望带动业绩提升。</p><p mp-original-font-size="16" mp-original-line-height="28.799999237060547">8股净利润同比下降。其中<span mp-original-font-size="16" mp-original-line-height="28.799999237060547"><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002413" code="002413">雷科防务</a></span>降幅最高，为201.53%，主要是受到国家相关部门税收政策调整以及主要原材料价格大幅上涨，采购成本明显增加的影响。此外，公司还对前期收购的子公司计提了大额商誉减值准备。另有<span mp-original-font-size="16" mp-original-line-height="28.799999237060547"><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS688316" code="688316">青云科技</a>-U</span>和<span mp-original-font-size="16" mp-original-line-height="28.799999237060547"><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002951" code="002951">金时科技</a></span>净利润同比降幅逾60%。（数据宝 张智博）</p><p style="text-align:center"><img src="https://data.stcn.com/djsj/202203/W020220314295124311607.png" title="6951647170689_.pic.jpg" alt="6951647170689_.pic.jpg" width="300px" height="328.24760244115083px" style="width: 300px; height: 328.248px;" oldsrc="W020220314295124311607.png" referrerpolicy="no-referrer"></p><p mp-original-font-size="17" mp-original-line-height="25.600000381469727"><span mp-original-font-size="14" mp-original-line-height="25.600000381469727">声明：数据宝所有资讯内容不构成投资建议，股市有风险，投资需谨慎。</span></p>
  
</div>
            